Edition:
United Kingdom

Kyorin Holdings Inc (4569.T)

4569.T on Tokyo Stock Exchange

2,297JPY
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
¥2,297
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
165,224
52-wk High
¥2,469
52-wk Low
¥1,969

Latest Key Developments (Source: Significant Developments)

Kyorin Holdings unit and FAES Farma sign agreement on development and distribution of Imidafenacin in Latin America
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Kyorin Holdings Inc <4569.T>:Says KYORIN Pharmaceutical Co., Ltd., a subsidiary of the company, has executed a collaboration agreement with FAES FARMA, S.A. for the exclusive development and distribution rights to Imidafenacin, a treatment for overactive bladder (OAB) that was discovered and developed by Kyorin Pharmaceutical, in Latin America (13 central and south countries including Brazil and Mexico).  Full Article

Suzuken unit signs license agreement regarding SK-1404 for treatment of frequent urination at night
Thursday, 29 Mar 2018 

March 29 (Reuters) - Suzuken Co Ltd <9987.T>:Says its unit SANWA KAGAKU KENKYUSHO CO,LTD signs license agreement with KYORIN Pharmaceutical Co Ltd, which is unit of Kyorin Holdings Inc <<<4569.T>>>, regarding SK-1404 for treatment of frequent urination at night.  Full Article

Kyorin Holdings says integration of production function
Tuesday, 19 Dec 2017 

Dec 19(Reuters) - Kyorin Holdings Inc <4569.T>:Says its Tokyo-based drug unit, which was established in October, will take over Noshiro plant of unit Kyorin Pharmaceutical Company, Limited and manufacture division of KYORIN Rimedio Co.,Ltd., effective April 1, 2018.Says the Tokyo-based drug unit will merge with the company's Shiga-based unit KYORIN Pharmaceutical Facilities Co.,Ltd, effective April 1, 2018.Says KYORIN Pharmaceutical Facilities Co.,Ltd will be dissolved after the merger .  Full Article

Kyorin Holdings unit signs production and marketing license agreement with vietnamese pharmaceutical company
Wednesday, 22 Nov 2017 

Nov 22(Reuters) - Kyorin Holdings Inc <4569.T>:Says its subsidiary KYORIN Rimedio Co., Ltd. has agreed to provide a production and marketing license for generic medicine to BinhDinh Pharmaceutical and Medical Equipment JSC.Says pursuant to the terms of the license agreement, KYORIN Rimedio will license the production rights for Losarhyd Combination Tablets LD and two other products to BIDIPHAR in return for a one-time lump sum payment upon conclusion of the agreement and KYORIN Rimedio will also receive royalties.  Full Article

BRIEF-Suzuken unit signs license agreement regarding SK-1404 for treatment of frequent urination at night

* Says its unit SANWA KAGAKU KENKYUSHO CO,LTD signs license agreement with KYORIN Pharmaceutical Co Ltd, which is unit of Kyorin Holdings Inc, regarding SK-1404 for treatment of frequent urination at night